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in patients treated for left-sided breast cancer without 
breath-hold were higher when compared to those with right-
sided breast cancers and to those with left-sided breast 
cancer treated with breath-hold. See the Table and the 
Figure. 
Group 
Mean CAC  
LAD_baseline 
Mean CAC  
Overall_baseline  
Mean CAC  
LAD_3 years 
Mean CAC  
Overall_3 years  
R (n=20) 14.5 (0-105) 80.1 (0-825) 
 
29.9 (0-255) 138 (0-1334) 
 
L-BH (n=18) 49.3 (0-334) 75.2(0-477) 
 
77.3 (0-634) 138.3 (0-1055) 
 
L+BH (n=61) 19.3 (0-401) 35.7 (0-645) 
 
28.8 (0-509) 64.9 (0-1039) 
 
 
 
 
Figure left and middle: Mean calcium score increase in time 
for the LAD and overall CAC score. Figure right: Mean CAC 
score: LAD minus RCA. 
Blue solid line: Left-sided breast cancer patients, group L-BH. 
Black dashed line: Right-sided breast cancer patients, group 
R. Red dotted line: Left-sided breast cancer patients treated 
in breath-hold, group L+BH. Note: the scales in the figure 
differ. 
Conclusions: Breath-hold in breast conserving radiotherapy 
leads to a less pronounced increase of CT based CAC scores. 
Therefore, breath-hold is probably useful to prevent the 
development of radiation-induced coronary artery disease. 
The drawbacks of our study were the small numbers and the 
relatively short follow-up period. 
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Purpose/Objective: Loco-regional recurrences in post-
irradiated breast cancers pose a major therapeutic challenge 
and could severely compromise patients' quality of life. Since 
in most cases, patients usually have co-existing systemic 
disseminated disease, a sustainable complete local regression 
of the recurrences, without treatment induced morbidity 
could provide an effective palliation and improve theirquality 
of life. Local hyperthermia (HT) along with moderate doses 
of re-irradiation (ReRT)has been used in various single-arm 
(ReRT+HT) and two-arm clinical trials (randomized and 
nonrandomized, ReRTvs. ReRT+HT). The present study 
conducts a systematic review and meta-analysis on the 
outcome of these trials. 
Materials and Methods: Using the appropriate MeSH and 
Boolean function, a detailed search was conductedas per the 
PRISMA guidelines. 2,047 abstracts were screenedfrom the 10 
databases used for search (Fig). Only those studies which had 
received prior loco-regional RT as a part of their primary 
management and were treated with ReRT and HT alone were 
considered. Patients who had undergone surgery for the loco-
regional recurrences were subjected to concurrent 
chemotherapy were not considered. End point evaluation was 
complete loco-regional response (CR) following ReRT and HT.  
 
 
Results: A total of 43 full papers were shortlisted and 
reviewed after extensive database search, and 24studies 
were selected for detailed review based on pre-defined 
selection criteria. Six of these were two-arm (randomized, 
n=4; nonrandomized, n=2) while 18 were single-arm studies 
resulting in a total of 1,319 patients of which 1,162 received 
ReRT and HT.  
Primary RT at doses ranging from 40 to60 Gy (mean + SD: 
50.6+ 6.1 Gy) was received by these patients between 37 and 
72 months before being considered for ReRT. Hyperthermia 
was mostly delivered by microwaves (91.7%), twice a week 
and usually following RT (79.2%). A temperature ranging from 
40.6 -43°C (42.4+ 0.7°C) was achieved during HT which 
lasted for a mean duration of 53.5 min. ReRT doses ranged 
from 24 -60 Gy (36.3 +8.1Gy) and delivered at 1.8 to 4 Gy/fr 
(2.85+0.9 Gy). 
Two-arm studies included 494 patients, and a CR of 62.8% 
and 39.3% was observed with ReRT+HT and ReRTrespectively, 
giving an odds ratio of 2.9 (95% CI: 1.8-4.6, p<0.001; Q=6.4, 
I2= 22.2, p=0.26). The risk ratio was 1.6 (95% CI: 1.2-2.0) in 
favor of achieving a CR with ReRT+HT compared to ReRT 
alone. For 18 single-arm studies, a CR of 64.6% was reported 
from the 825 patients resulting in an event rate of 0.6 (95% 
CI: 0.5-0.6, p<0.001; Q=33.8, I2= 49.7, p=0.008). Local 
control with ReRT +HT at 1 and 2 year were 57.1% and 48.5% 
respectively. Mean acute and late grade III/IV toxicities with 
ReRT +HT were reported as 13.4% and 3.9%. 
Conclusions: ReRT with HTsubstantially increases the 
probability of achieving CRs in loco-regional recurrences in 
pre-irradiated patients with low acute and late morbidities.  
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